<html><head>







 
 
  







<title> DNA bar coding and pyrosequencing to identify rare HIV drug
resistance mutations -- Hoffmann et al., 10.1093/nar/gkm435 -- Nucleic
Acids Research</title>


	<script language="JavaScript">
	<!--
	function startTarget(windowname,wid,hei) {
	
	var dotpos = windowname.indexOf(".");
	if (dotpos > -1)
	{
	var tempwn = windowname.substring(0,dotpos) +
		windowname.substring(dotpos + 1, windowname.length);
	windowname = tempwn;
	}
	var sizestring = 'width=' + wid + ',height=' + hei;
	window.open('',windowname,'scrollbars,resizable,' + sizestring + '\'');
	}
	// -->
	</script>




	<!-- has inhead tag -->
	
		 
	
		
	<script language="JavaScript">
		<!--
			function RightslinkPopUp( title, date, author, copyright, contentID, volumeNum, issueNum, startPage, endPage, issn, eissn )
			{
				var url = "https://s100.copyright.com/AppDispatchServlet"; 
				var location = url
				+ "?publisherName=" + escape("oup")
				+ "&publication=" + escape("nar")
				+ "&title=" + escape(title)
				+ "&publicationDate=" + escape(date)
				+ "&author=" + escape(author)
				+ "&copyright=" + escape(copyright)
				+ "&contentID=" + escape(contentID)
				+ "&volumeNum=" + escape(volumeNum)
				+ "&issueNum=" + escape(issueNum)
				+ "&startPage=" + escape(startPage)
				+ "&endPage=" + escape(endPage)
				+ "&issn=" + escape(issn)
				+ "&eissn=" + escape(eissn)
				+ "&orderBeanReset=true";
				
				PopUp = window.open( location,'Rightslink','location=no,toolbar=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,width=650,height=550');
			}
		// -->
	</script>

	
		
<style type="text/css"><!--
	@media screen,print,handheld
{
    .notonscreen { display: none; }
}
--></style>
<!-- ac in the head available -->

 

		<style type="text/css"><!--
table.content_box_outer_table {
	padding-left:10px;
	padding-bottom:5px;
	padding-top:0px;
	padding-right:0px;
	}

table.content_box_outer_table_in_sidebar_frame {
	padding-left:10px;
	padding-bottom:0px;
	padding-top:10px;
	padding-right:10px;
	}

table.content_box_inner_table {
	background-color:#f0f0f0;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:5px;
	}

table.content_box_pdfinframes {
	padding-top:0px;
	padding-left:0px;
	padding-right:0px;
	padding-bottom:4px;
	}

td.content_box_title_highlight {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#000E4F;
	font-size:120%;
	font-weight:bold;
	text-align:center;
	padding:1px;
	vertical-align:middle;
	}

td.content_box_title {
	font-family:"Trebuchet MS",Verdana,Arial,Helvetica,sans-serif;
	font-style:italic;
	color:#ffffff;
	background-color:#828282;
	font-size:120%;
	font-weight:bold;
	padding:1px;
	text-align:center;
	vertical-align:middle;
	}

td.content_box_space_between_sections {
	padding-top:2px;
	}

td.content_box_arrow {
	text-align:right;
	padding-left:5px;
	padding-right:0px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_item {
	text-align:left;
	vertical-align:top;
	padding-left:3px;
	padding-right:5px;
	padding-top:0px;
	padding-bottom:3px;
	}

td.content_box_pdfinframes_citation_cell {
	background-color:#ffffff;
	border:1px #000000 solid;
	padding:3px;
	font-family:Verdana,Arial,Helvetica,sans-serif;
	font-size:65%;
	text-align:left;
	}


font.openaccess {
	font-weight:bold;
	padding-left:3px;
	padding-right:3px;
	background-color:#ffffff;
	}
font.openaccess_open {
	color:#000000;
	}
font.openaccess_access {
	color:#cc0000;
	}
font.openaccess_oa {
	}
.content_box_openaccess_title {
	text-align:center;
	white-space:nowrap;
	background-color:#BABABA;
	}




div.referrer-based-search-line {
	font-family: arial,sans-serif;
	font-size: 0.75em;
	background-color: #009918;
	padding: 3px 25px;
	margin: 0px 4px 5px 0px;
}

div.referrer-based-search-line .search-terms{
	font-weight: bold;
}

div.referrer-based-search-line .collection-name{
	font-style: italic;
}

@media screen,print,handheld
{
    .notonscreen { display: none; }
}
--></style>

		
<!-- START HIGHWIRE INHEAD.MC -->
<meta http-equiv="Content-type" content="text/html; charset=ISO-8859-1">
<style type="text/css" media="screen">
@import "/resource/css/hw.css";
@import "/resource/css/nar.css";
</style>
<link rel="stylesheet" type="text/css" href="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/print.css" media="print">
<script type="text/javascript" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/main.js"></script>
<!-- END HIGHWIRE INHEAD.MC -->

		
	    <script language="javascript">
		<!-- 
	function popwin(url,wid,hei,fromtop,fromleft) {
		var winPref = "channelmode=no,toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=auto,resizable=no,width=" + wid + ",height=" + hei + ",top=" + fromtop + ",left=" + fromleft;
		window.open(url, "popwin", winPref);
	}
	// -->
	</script>
        <script type="text/javascript" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/xmlhttprequest.js"></script>
<script type="text/javascript" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/utility.js"></script>
<script type="text/javascript" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/callback.js"></script>

	
		
	
	
<link rel="alternate" type="application/rss+xml" title="Nucl. Acids Res. current issue" href="http://nar.oxfordjournals.org/rss/current.xml"> 
<link rel="alternate" type="application/rss+xml" title="Nucl. Acids Res. latest 3 issues" href="http://nar.oxfordjournals.org/rss/recent.xml"> 
<link rel="alternate" type="application/rss+xml" title="Nucl. Acids Res. Advance Access articles" href="http://nar.oxfordjournals.org/rss/ahead.xml"> 


<meta name="robots" content="nofollow">



<meta name="citation_journal_title" content="Nucleic Acids Research">
<meta name="citation_publisher" content="Oxford Univ Press">
<meta name="citation_issn" content="0305-1048">

<meta name="citation_authors" content="Hoffmann, Christian; Minkah, Nana; Leipzig, Jeremy; Wang, Gary; Arens, Max Q.; Tebas, Pablo; Bushman, Frederic D.">
<meta name="citation_title" content="DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations">
<meta name="citation_date" content="06/18/2007">

<meta name="citation_firstpage" content="gkm435v1">
<meta name="citation_id" content="gkm435v1">
<meta name="citation_mjid" content="nar;gkm435v1">
<meta name="citation_doi" content="10.1093/nar/gkm435">
<meta name="citation_abstract_html_url" content="http://nar.oxfordjournals.org/cgi/content/abstract/gkm435v1">
<meta name="citation_fulltext_html_url" content="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1">
<meta name="citation_pdf_url" content="http://nar.oxfordjournals.org/cgi/reprint/gkm435v1.pdf">
<meta name="citation_pmid" content="17576693">
<meta name="citation_access" content="all">

<meta name="dc.Contributor" content="Hoffmann, Christian">
<meta name="dc.Contributor" content="Minkah, Nana">
<meta name="dc.Contributor" content="Leipzig, Jeremy">
<meta name="dc.Contributor" content="Wang, Gary">
<meta name="dc.Contributor" content="Arens, Max Q.">
<meta name="dc.Contributor" content="Tebas, Pablo">
<meta name="dc.Contributor" content="Bushman, Frederic D.">
<meta name="dc.Title" content="DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations">
<meta name="dc.Identifier" content="10.1093/nar/gkm435">
<meta name="dc.Date" content="06/18/2007">

<meta name="ROBOTS" content="NOARCHIVE"> 

<!-- /our_journals/body.mc -->
</head><body class="general_page journal nar">


<a name="top"><!-- null --></a>


<!-- OAS SETUP begin -->
<script type="text/javascript">
<!--
//configuration
OAS_url ='http://oas.oxfordjournals.org/RealMedia/ads/';
OAS_listpos = 'Top,Bottom';
OAS_query = '?';
OAS_sitepage = location.hostname + location.pathname;
//end of configuration
OAS_version = 10;
OAS_rn = '001234567890'; OAS_rns = '1234567890';
OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
function OAS_NORMAL(pos) { document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + OAS_query + '" target=_top>');
document.write('<img scr="' + OAS_url + 'adstream_nx.ads?' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + OAS_query + '" border=0></a>');
}
//-->
</script>
<script type="text/javascript">
<!--
OAS_version = 11;
if (navigator.userAgent.indexOf('Mozilla/3') != -1)
OAS_version = 10;
if (OAS_version >= 11)
document.write('<SC'+'ript language=JavaScript1.1 SRC="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + OAS_query + '"><\/SCRIPT>');
//-->
</script><script language="JavaScript1.1" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/1293020914TopBottom.js"></script><script type="text/javascript">
<!-- document.write('');
function OAS_AD(pos) {
if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined')
OAS_RICH(pos);
else
OAS_NORMAL(pos);
}
//-->
</script>
<!-- OAS SETUP end -->
<!-- test -->
<div id="wrap">
<p class="hide">
<a href="#content">Skip Navigation</a>
</p>
<div id="secondary_nav">
<strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
<ul>
<li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
<li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
<li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My Account</span></a></li>
</ul>
</div>
<div id="header">
<h1 id="page_title" title="Nucleic Acids Research"><a href="http://nar.oxfordjournals.org/"><span>Nucleic Acids Research</span></a></h1>
</div>
<div id="primary_nav">
<ul>
<li id="nav_about_this_journal" title="About This Journal"><a href="http://www.oxfordjournals.org/nar/about.html"><span>About This Journal</span></a></li>
<li id="nav_contact_this_journal" title="Contact This Journal"><a href="http://nar.oxfordjournals.org/cgi/feedback/"><span>Contact This Journal</span></a></li>
<li id="nav_subscriptions" title="Subscriptions"><a href="http://nar.oxfordjournals.org/subscriptions/index.dtl"><span>Subscriptions</span></a></li>
<li id="nav_current_issue" title="Current Issue"><a href="http://nar.oxfordjournals.org/current.dtl"><span>Current Issue</span></a></li>
<li id="nav_archive" title="Archive"><a href="http://nar.oxfordjournals.org/archive/"><span>Archive</span></a></li>
<li id="nav_search" title="Search"><a href="http://nar.oxfordjournals.org/search.dtl"><span>Search</span></a></li>
</ul>
</div>




















<div id="user_nav">
<!-- subline logic: standard default -->








	
	

	





	
	
	
	
		  
	<!-- NOT GUEST -->
	

	



 


</div>



<div id="breadcrumbs">
<ul>
<li class="first">
<a href="http://www.oxfordjournals.org/">Oxford Journals</a>
</li>

<li>
<a href="http://www.oxfordjournals.org/subject/life_sciences//">Life Sciences</a>
</li>


<li><a href="http://nar.oxfordjournals.org/">Nucleic Acids Research</a></li>

<li><a href="http://nar.oxfordjournals.org/papbyrecent.dtl">Nucleic Acids Research Advance Access</a></li>

<li>10.1093/nar/gkm435</li>

</ul>
</div>

<div id="articlenav">

</div> <div id="content">
<a name="content"></a>
<div id="hw">
<!--OAS AD'Top'begin-->
<div id="oas_top">
<script type="text/javascript">
<!--
OAS_AD('Top');
//-->
</script><a href="http://oas.oxfordjournals.org/RealMedia/ads/click_lx.ads/nar.oxfordjournals.org/cgi/content/full/gkm435v1/L34/468284755/Top/OxfordJournals/H_NAR_OJ_Any_05AUG08_EG/NAR_DNA_Aging.gif/6761755769456b3171746f4141434947?x" target="_top"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/NAR_DNA_Aging.gif" alt="Access the NAR DNA Aging Collection" border="0"></a>
</div>
<!--OAS AD'Top'end-->











 
	












	






	
		 


	
	
	


 




        
        	
			
			
			
        
        	
			
			
			
        
         <br><font color="#a70716" size="-1"><strong>
        
         <br>
         Nucleic Acids Research Advance Access published online on June 18, 2007
        
         </strong></font><font size="-1"><br>Nucleic Acids Research, doi:10.1093/nar/gkm435
                <br>
                
       </font>
    


	 
 






 



 
	 
		  
			
	
		<table class="content_box_outer_table" align="right">
		
		
			<tbody><tr>
			<td>
		
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tbody><tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
				
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				
					
				
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/abstract/gkm435v1">
				Abstract</a></strong>
				
					 						<img alt="Freely available" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/free.gif" border="0" height="7" width="32">
					
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	
	
	
	
	
	
	

	
		
		
	
	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		<strong>
		
		
		
			<a href="http://nar.oxfordjournals.org/cgi/reprint/gkm435v1">
		Print PDF (173K) <img alt="Freely available" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/free.gif" border="0" height="7" width="32"> </a>

 
		
		</strong>
		</td></tr>
	
	

	
	
	
	
	

	
	
	

	
	


 
	 

		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		<strong>
		
		
			<a href="http://nar.oxfordjournals.org/cgi/screenpdf/gkm435v1">
		Screen PDF (175K) <img alt="Freely available" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/free.gif" border="0" height="7" width="32"> </a> 
		
		</strong>
		</td></tr>
	



	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			
			

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435/DC1">
				Supplementary Material</a></strong>
			</td></tr>
			

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435/DC2">
				Supplementary Data</a></strong>
			</td></tr>
			

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435/DC3">
				Supplementary Data</a></strong>
			</td></tr>
			
			

			
	
	

	
		
	









	
		
	
		
		
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item"><font class="openaccess"><font class="openaccess_oa"><font class="openaccess_open">O</font><font class="openaccess_access">A</font></font></font><strong>
			All Versions of this Article:<br>
		
			<a href="http://nar.oxfordjournals.org/cgi/content/short/35/13/e91">
					35/13/e91</a>
			
		&nbsp;&nbsp;&nbsp;<font color="#000e4f"><em>most recent</em></font><br>
	

	
		
		
			
					gkm435v1
				
		</strong></td></tr>
	

	





	
	
	

	
		
	

	 

	
	
		  
    

	
	
	
	







		
	
		
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;saveAlert=no&amp;cited_by_criteria_resid=nar;gkm435v1&amp;return_type=article&amp;return_url=http%3A%2F%2Fnar.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2Fgkm435v1">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		
			
		

		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;saveAlert=no&amp;correction_criteria_value=gkm435v1&amp;return_type=article&amp;return_url=http%3A%2F%2Fnar.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2Fgkm435v1">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		
























			
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/mailafriend?url=http%3A%2F%2Fnar.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2Fgkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

	

		
		



			
			
			
		
	

		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		<strong>
		<a href="http://nar.oxfordjournals.org/cgi/search?qbe=nar;gkm435&amp;journalcode=nar&amp;minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=17576693&amp;link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		



			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=nar;gkm435v1">
				Add to My Personal Archive</a></strong>
			</td></tr>
		
		
	

		
		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
			<strong><a href="http://nar.oxfordjournals.org/cgi/citmgr?gca=nar;gkm435v1">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	



  			
		
		
		
	

	
	
	
	
	



	


		

		

	
	
	
		


	

	
	

	
		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
			<strong><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org%2Fjnls%2Flist%2Fnar%2Fspecial%2F18%2Fdefault.html">Commercial Re-use Guidelines<br>for Open Access NAR Content </a></strong>
		</td></tr>
	
	

	

	















	
		
			
				
				
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">Google Scholar</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AC.+author%3AHoffmann%22">
							Articles by Hoffmann, C.</a></strong>
						</td></tr>
				
				
			
				
			
				
			
				
			
				
			
				
			
				
				

						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AF.%20D.+author%3ABushman%22">
							Articles by Bushman, F. D.</a></strong>
						</td></tr>
				
				
			
		
		
	
	
	
		
	
	

		
			
				
					
						
						
						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=http://nar.oxfordjournals.org/cgi/content/abstract/gkm435v1&amp;link_type=GOOGLESCHOLARRELATED">Search for Related Content</a></strong>
						</td></tr>		
						
				
			
		
	










	





	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=17576693&amp;link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=Hoffmann+C&amp;link_type=AUTHORSEARCH">
							Articles by Hoffmann, C.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=Bushman+FD&amp;link_type=AUTHORSEARCH">
							Articles by Bushman, F. D.</a></strong>
						</td></tr>
				
			
		

		
	

	
















	















	


































	
		

	

		
			
		
	 
		











	

	








	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">Social Bookmarking</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
	<tr><td class="content_box_arrow"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		
			
			<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=CITEULIKE" title="CiteULike"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/citeulike.gif" alt="Add to CiteULike" border="0"></a>&nbsp;&nbsp;
			
		
			
		
			
			<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=CONNOTEA" title="Connotea"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/connotea.gif" alt="Add to Connotea" border="0"></a>&nbsp;&nbsp;
			
		
			
			<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=DEL_ICIO_US" title="Del.icio.us"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/delicious.gif" alt="Add to Del.icio.us" border="0"></a>&nbsp;&nbsp;
			
		
			
		
			
		
			
		
			
		
		<br><a href="http://www.oxfordjournals.org/help/features/index.html#socialbookmarking">What's this?</a>
	</td></tr>































	</tbody></table>
</td></tr></tbody></table> 


		
	



 







<p>
<!-- <rdf:RDF xmlns="http://creativecommons.org/ns#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
<License rdf:about="http://creativecommons.org/licenses/by-nc/2.0/uk/">
<permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
<permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
<requires rdf:resource="http://creativecommons.org/ns#Notice"/>
<requires rdf:resource="http://creativecommons.org/ns#Attribution"/>
<prohibits rdf:resource="http://creativecommons.org/ns#CommercialUse"/>
<permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
</License>
<item rdf:about="">
<title>DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations</title>
<dc:title>DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations</dc:title>
<dc:creator>Hoffmann, Christian</dc:creator>
<dc:creator>Minkah, Nana</dc:creator>
<dc:creator>Leipzig, Jeremy</dc:creator>
<dc:creator>Wang, Gary</dc:creator>
<dc:creator>Arens, Max Q.</dc:creator>
<dc:creator>Tebas, Pablo</dc:creator>
<dc:creator>Bushman, Frederic D.</dc:creator>
<dc:identifier>10.1093/nar/gkm435</dc:identifier>
<dc:source>Nucleic Acids Research 2007, 2007:gkm435v1</dc:source>
<dc:date>2007-06-18</dc:date>
<prism:publicationName>Nucleic Acids Research</prism:publicationName>
<prism:publicationDate>2007-06-18</prism:publicationDate>

<prism:section>Molecular Biology</prism:section>
<prism:startingPage>gkm435v1</prism:startingPage>
</item>
</rdf:RDF> -->
 





	
	
	
	
	
	
    
	
	
	
	
		<font size="-1">
<a href="http://nar.oxfordjournals.org/misc/terms.shtml">© 2007 The Author(s)<sup> </sup><br>This
is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.</a>
</font><br>
<table cellpadding="0" cellspacing="0"><tbody><tr><td><hr noshade="noshade" size="1"><h3>Molecular Biology</h3></td></tr></tbody></table>
</p><h2>
DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations</h2>
<strong>
<nobr>Christian Hoffmann<sup>1</sup></nobr>, 
<nobr>Nana Minkah<sup>1</sup></nobr>, 
<nobr>Jeremy Leipzig<sup>1</sup></nobr>, 
<nobr>Gary Wang<sup>1</sup></nobr>, 
<nobr>Max Q. Arens<sup>3</sup></nobr>, 
<nobr>Pablo Tebas<sup>2</sup></nobr> and 
<nobr>Frederic D. Bushman<sup>1</sup><sup>,*</sup></nobr>
</strong><p>

<sup>1</sup>Department of Microbiology and <sup>2</sup>Division of
Infectious Diseases, Department of Medicine, University of Pennsylvania
School of Medicine, 3610 Hamilton Walk, Philadelphia, PA 19104-6076 and
<sup>3</sup>Department of Pediatrics, Washington University School of Medicine, One Children's Place, St Louis, MO 63110, USA
</p><p>

<font size="-1">*To whom correspondence should be addressed. Tel:  1 (215) 573 8732; Fax:  1 (215) 573 4856; Email:  <span id="em0"><a href="mailto:bushman@mail.med.upenn.edu">bushman@mail.med.upenn.edu</a></span><script type="text/javascript"><!--
 var u = "bushman", d = "mail.med.upenn.edu"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></script></font></p><p>
<font size="-1">Received March  2, 2007.</font>  <font size="-1">Revised March  2, 2007.</font>  <font size="-1">Accepted May 15, 2007.</font></p><p>


<a name="ABS"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
ABSTRACT
</font></th></tr></tbody></table>
<table align="right" border="1" cellpadding="5"><tbody><tr><th align="left"><font size="-1">
<a href="#top"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">TOP<br></a>
<img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/dot.gif" border="0" height="9" hspace="5" width="11"><font color="#464c53">ABSTRACT</font><br>
<a href="#SEC1"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">INTRODUCTION<br></a>
<a href="#SEC2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">MATERIALS AND METHODS<br></a>
<a href="#SEC3"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">RESULTS<br></a>
<a href="#SEC4"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">DISCUSSION<br></a>
<a href="#SEC5"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">SUPPLEMENTARY DATA<br></a>
<a href="#BIBL"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>


Treatment of HIV-infected individuals with antiretroviral agents<sup> </sup>selects for drug-resistant mutants, resulting in frequent treatment<sup> </sup>failures. Although the major antiretroviral resistance mutations<sup> </sup>are routinely characterized by DNA sequencing, treatment failures<sup> </sup>are still common, probably in part because undetected rare resistance<sup> </sup>mutations facilitate viral escape. Here we combined DNA bar<sup> </sup>coding and massively parallel pyrosequencing to quantify rare<sup> </sup>drug resistance mutations. Using DNA bar coding, we were able<sup> </sup>to analyze seven viral populations in parallel, overall characterizing<sup> </sup>118 093 sequence reads of average length 103 bp. Analysis of<sup> </sup>a control HIV mixture showed that resistance mutations present<sup> </sup>as 5% of the population could be readily detected without false<sup> </sup>positive calls. In three samples of multidrug-resistant HIV<sup> </sup>populations from patients, all the drug-resistant mutations<sup> </sup>called by conventional analysis were identified, as well as<sup> </sup>four additional low abundance drug resistance mutations, some<sup> </sup>of which would be expected to influence the response to antiretroviral<sup> </sup>therapy. Methods for sensitive characterization of HIV resistance<sup> </sup>alleles have been reported, but only the pyrosequencing method<sup> </sup>allows all the positions at risk for drug resistance mutations<sup> </sup>to be interrogated deeply for many HIV populations in a single<sup> </sup>experiment.<sup> </sup></p><p>





<a name="SEC1"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
INTRODUCTION
</font></th></tr></tbody></table>
<table align="right" border="1" cellpadding="5"><tbody><tr><th align="left"><font size="-1">
<a href="#top"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">TOP<br></a>
<a href="#ABS"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">ABSTRACT<br></a>
<img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/dot.gif" border="0" height="9" hspace="5" width="11"><font color="#464c53">INTRODUCTION</font><br>
<a href="#SEC2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">MATERIALS AND METHODS<br></a>
<a href="#SEC3"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">RESULTS<br></a>
<a href="#SEC4"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">DISCUSSION<br></a>
<a href="#SEC5"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">SUPPLEMENTARY DATA<br></a>
<a href="#BIBL"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

Antiretroviral resistance is a major threat to successful anti-HIV<sup> </sup>treatment. This problem is more frequent among individuals that<sup> </sup>started therapy in the 1990s, who were treated sequentially<sup> </sup>with single antiviral agents (<a href="#B1">1</a>), allowing sequential development<sup> </sup>of resistance to each treatment. Therapy with combinations of<sup> </sup>antiretroviral drugs is more effective, but nevertheless up<sup> </sup>to 50% of individuals currently in care in the US harbor HIV-resistant<sup> </sup>viruses (<a href="#B2">2</a>). These resistant strains can also be transmitted&#8212;more<sup> </sup>than 15% of recently infected individuals have acquired viruses<sup> </sup>that are resistant to at least one of the major antiretroviral<sup> </sup>classes (<a href="#B3">3&#8211;5</a><a href="#B4"></a><a href="#B5"></a>). Current treatment guidelines in the United<sup> </sup>States recommend resistance testing before beginning or changing<sup> </sup>antiretroviral therapy.<sup> </sup></p><p>

In the developing world, where much of the burden of HIV infection<sup> </sup>is concentrated, combination therapy is increasingly available.<sup> </sup>A sharp increase in drug resistance is expected as patients<sup> </sup>become more treatment experienced. Unfortunately, resistance<sup> </sup>genotyping is generally unavailable in the developing world<sup> </sup>due to the prohibitive expense.<sup> </sup></p><p>

Genotypic and phenotypic methods are commonly used to detect<sup> </sup>antiviral resistance in clinical specimens. Genotypic methods<sup> </sup>use bulk sequencing of the protease (PR) and reverse transcriptase<sup> </sup>(RT) coding regions, which reports the sequence of the predominant<sup> </sup>circulating HIV variants. Resistance mutations conferring reduced<sup> </sup>sensitivity to the three most widely used drug classes (nucleoside<sup> </sup>and non-nucleoside RT inhibitors and PR inhibitors) are well<sup> </sup>characterized, allowing probable resistance patterns to be inferred<sup> </sup>from sequence information. Phenotypic methods rely on cloning<sup> </sup>the RT and PR-coding regions from patient samples into a standard<sup> </sup>HIV plasmid backbone, allowing generation of viral stocks and<sup> </sup>functional analysis of viral drug sensitivity in short-term<sup> </sup>culture (<a href="#B1">1</a>).<sup> </sup></p><p>

Several studies have demonstrated that minor drug-resistant<sup> </sup>HIV populations that are not detectable in the standard assays<sup> </sup>can impair the response to therapy (<a href="#B6">6</a>,<a href="#B7">7</a>). This problem is particularly<sup> </sup>apparent in studies of pregnant women that received single doses<sup> </sup>of nevirapine, a non-nucleoside reverse transcriptase inhibitor<sup> </sup>(NNRTI), at the time of delivery to prevent vertical transmission<sup> </sup>of HIV. In these patients, the presence of minor populations<sup> </sup>with resistance to nevirapine&#8212;which were often undetectable<sup> </sup>by conventional sequencing&#8212;compromised the response to<sup> </sup>subsequent NNRTI therapy (<a href="#B8">8</a>,<a href="#B9">9</a>).<sup> </sup></p><p>

A variety of technologies have been devised to allow characterization<sup> </sup>of minor HIV drug-resistant populations (<a href="#B7">7</a>,<a href="#B10">10</a>,<a href="#B11">11</a>). In one method,<sup> </sup>microarrays were designed to interrogate positions of drug resistance<sup> </sup>mutations (<a href="#B12">12</a>). This technique allows analysis of many genomic<sup> </sup>positions in a single experiment, but the method has not been<sup> </sup>widely used, in part due to the high cost of each test. Another<sup> </sup>method involves allele-specific RT-PCR, which allows sensitive<sup> </sup>detection of single drug resistance mutations (<a href="#B10">10</a>). A third<sup> </sup>approach takes advantage of the massively parallel polony sequencing<sup> </sup>method (<a href="#B11">11</a>), and a fourth uses an early version of pyrosequencing<sup> </sup>to query single nucleotide positions for possible mutations<sup> </sup>(<a href="#B13">13</a>). However, except for the microarray method, all of the<sup> </sup>above methods queried individual base pairs at a time (<a href="#B10">10</a>).<sup> </sup>Given that there are over 60 amino acid positions just in PR<sup> </sup>and RT that can affect resistance to the three widely used drug<sup> </sup>classes, these methods are time consuming and difficult to use<sup> </sup>for comprehensive analysis. An ideal method for investigating<sup> </sup>drug resistance mutations would yield many complete sequences<sup> </sup>of HIV genomic regions at risk for mutations for each viral<sup> </sup>population, and allow analysis of many samples of HIV populations<sup> </sup>in a single experiment.<sup> </sup></p><p>

We have adapted pyrosequencing (<a href="#B14">14</a>), combined with a DNA bar<sup> </sup>coding system (<a href="#B15">15</a>,<a href="#B16">16</a>), to characterize rare drug-resistant HIV<sup> </sup>variants in many samples in parallel. In a single experiment,<sup> </sup>we determined 118 093 sequences from <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">100 bp segments of the<sup> </sup>PR and RT-coding regions for seven samples of viral populations<sup> </sup>(<a href="#T1">Table 1</a>). These data identified a variety of minor drug resistance<sup> </sup>alleles in patient samples of potential clinical significance,<sup> </sup>and demonstrate the feasibility of using pyrosequencing for<sup> </sup>efficient HIV genotyping. Multiplex analysis of many bar coded<sup> </sup>samples in a single sequencing experiment offers the potential<sup> </sup>to drive down the cost of each genotype determination.<sup> </sup></p><p>

<a name="T1"><!-- null --></a>
<br clear="all"></p><center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
<strong>View this table:</strong><br>
<nobr><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/T1">[in this window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/content-nw/full/gkm435v1/T1" onclick="startTarget('T1', 500, 400); this.href='/cgi/content-nw/full/gkm435v1/T1'" onmouseover="window.status='View figure in a separate window'; return true" target="T1">[in a new window]</a><br>
<br>&nbsp;</nobr>
</td><td align="left" valign="top">
<b>Table 1.</b> Viral populations characterized in this study<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


<a name="SEC2"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
MATERIALS AND METHODS
</font></th></tr></tbody></table>
<table align="right" border="1" cellpadding="5"><tbody><tr><th align="left"><font size="-1">
<a href="#top"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">TOP<br></a>
<a href="#ABS"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">ABSTRACT<br></a>
<a href="#SEC1"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">INTRODUCTION<br></a>
<img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/dot.gif" border="0" height="9" hspace="5" width="11"><font color="#464c53">MATERIALS AND METHODS</font><br>
<a href="#SEC3"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">RESULTS<br></a>
<a href="#SEC4"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">DISCUSSION<br></a>
<a href="#SEC5"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">SUPPLEMENTARY DATA<br></a>
<a href="#BIBL"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

<strong>Nucleic acid purification</strong><br>

DNA primers for PCR amplification were obtained from Invitrogen<sup> </sup>(Carlsbad, CA, USA). The HIV LAI plasmid (pLAI) was obtained<sup> </sup>from Dr Michael Emerman (Fred Hutchinson Cancer Research Center).<sup> </sup>HIV LAI particles were made by transfection of the pLAI and<sup> </sup>pVSV-G into 293T cells using standard methods. Supernatants<sup> </sup>were collected 3 days after transfection, concentrated by centrifugation,<sup> </sup>then treated with DNAse I to remove possible DNA carried over<sup> </sup>from the initial transfection. HIV NL4-3 particles were made<sup> </sup>similarly but without adding the pVSV-G plasmid. The following<sup> </sup>viral stocks were obtained from the AIDS Reference Reagent Repository:<sup> </sup>HIV NL4-3 (L10R/M46I/L63P/V82T/I84V; Catalog #2840); HIV subtype<sup> </sup>A (Catalog #7683); HIV subtype B (Catalog #7686); HIV subtype<sup> </sup>C (Catalog #7694); HIV subtype D (Catalog #7699); HIV subtype<sup> </sup>E (Catalog #7701).<sup> </sup><p>

HIV RNA from patient plasma samples was purified in the high-throughput<sup> </sup>facility at the Children's Hospital of Philadelphia using the<sup> </sup>Magna-Pure System (Roche) by Dr R. Hodinka. Viral loads were<sup> </sup>patient 1: 736 000 c/ml; patient 2: 105 000 c/ml; patient 3:<sup> </sup>105 000 c/ml. Other HIV RNA samples were purified using the<sup> </sup>Illustra RNAspin mini RNA Isolation Kit (GE Health Care, Piscataway,<sup> </sup>NJ, USA).<sup> </sup></p><p>

<strong>PCR amplification</strong><br>

For the primer design, representative sequences (341 total)<sup> </sup>from subtypes A&#8211;D and G were downloaded from the Los Alamos<sup> </sup>HIV Database and Compendia (<a href="http://www.hiv.lanl.gov/">http://www.hiv.lanl.gov</a>). Subtype<sup> </sup>consensus sequences were formed by aligning sequences within<sup> </sup>each subtype, then &#8216;Pan-HIV&#8217; primers were designed<sup> </sup>to anneal to sequences conserved among subtypes (Supplementary<sup> </sup>Table 1).<sup> </sup></p><p>

All samples were amplified using the OneStep RT-PCR Kit (QIAGEN,<sup> </sup>Valencia, CA, USA) following the manufacturer's instructions.<sup> </sup>RNasin RNAse inhibitor (Promega, Madison, WI, USA) was added<sup> </sup>to the reaction to a final concentration of 0.5 units/µl.<sup> </sup>Five thousand copies of nucleic acid templates per reaction<sup> </sup>were used for the LAI DNA, LAI RNA and NL4-3 RNA mixture. For<sup> </sup>the patient samples, 10 µl of eluted material from the<sup> </sup>nucleic acid extraction was used as template. The RT-PCR reaction<sup> </sup>was carried out using a GeneAmp® PCR System 9700 (Applied<sup> </sup>Biosystems, Foster City, CA, USA). The program used was: 1 cycle<sup> </sup>of 45°C for 45 min followed by 15 min at 95°C; 14 touch-down<sup> </sup>cycles with annealing temperature from 55°C to 48°C<sup> </sup>for 30 s followed by 26 cycles with annealing temperature of<sup> </sup>48°C for 30 s. A final extension of 10 min at 72°C was<sup> </sup>used. The denaturing and extension temperatures were 94°C<sup> </sup>and 72°C, respectively, for all cycles. The estimated error<sup> </sup>rates for the amplification step using Taq polymerase is 2&#8211;3<sup> </sup>misincorporation events in 100 000, and for the RT step &lt;1<sup> </sup>substitution in 30 000 (estimates provided by Qiagen, Valencia,<sup> </sup>CA, USA).<sup> </sup></p><p>

PCR products were separated by electrophoresis on TAE agarose<sup> </sup>gels, slices containing the bands of interest were excised,<sup> </sup>DNA was extracted using the Qiagen Gel Extraction Kit (Valencia,<sup> </sup>CA, USA), then samples were pooled (75 ng per amplicon). For<sup> </sup>sequencing, the concentrations of DNA were adjusted to <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">5&#8211;15<sup> </sup>ng/µl.<sup> </sup></p><p>

<strong>Conventional analysis of HIV genotypes in patients</strong><br>

Patient 1 was treated with tenofovir, FTC, atazanvir and ritonavir;<sup> </sup>patient 2 is deceased and treatment history is unknown, and<sup> </sup>patient 3 was treated with retrovir (zidovudine), epivir (lamivudine;<sup> </sup>3TC) and viracept (nelfinavir). The conventional clinical analysis<sup> </sup>of HIV genotypes for the three patients studied was carried<sup> </sup>out as follows. Plasma viral RNA was extracted, amplified by<sup> </sup>RT-PCR (Roche Amplicor v 1.0; Roche Diagnostic Systems, Inc.,<sup> </sup>Branchburg, NJ, USA), and sequenced using the Viroseq HIV Genotyping<sup> </sup>System v 2.0 (Applied Biosystems, Foster City, CA, USA). The<sup> </sup>sequences were analyzed for the resistance mutations using the<sup> </sup>HIV Drug Resistance Database at Stanford University (<a href="http://hivdb.stanford.edu/">http://hivdb.stanford.edu/</a>)<sup> </sup>(<a href="#B17">17</a>), then calls were edited to match the slightly different<sup> </sup>catalog from the International AIDS Society Drug Resistance<sup> </sup>Mutations in HIV (Fall 2006) (<a href="#B2">2</a>).<sup> </sup></p><p>

<strong>Pyrosequencing</strong><br>

Pyrosequencing was carried out using the 454 Life Sciences Technology<sup> </sup>at the University of Florida. The pyrosequencing method, as<sup> </sup>implemented by 454 Life Sciences, involves the following steps.<sup> </sup>Genomic DNA samples of interest are amplified using primers<sup> </sup>that include 5' extensions providing binding sites for the 454<sup> </sup>A and B primers. DNA fragments are then mixed with beads that<sup> </sup>have bound on their surfaces oligonucleotides complementary<sup> </sup>to the primers. This step is carried out in dilute solution<sup> </sup>so that on average a single DNA strand binds to each bead. A<sup> </sup>dilute mixture of beads is then added to an oil&#8211;water<sup> </sup>emulsion, arranged so that on average each aqueous droplet contains<sup> </sup>a single bead with a single bound strand. PCR amplification<sup> </sup>is then carried out in the emulsion. Each DNA strand becomes<sup> </sup>amplified and then binds by sequence complementarity to the<sup> </sup>bead, thereby creating beads that are each conjugated to DNA<sup> </sup>strands of a single homogenous sequence. Beads with bound DNA<sup> </sup>are then distributed on a picotiter plate at a density of <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">150<sup> </sup>000 beads per plate. A primer is then bound to each DNA, and<sup> </sup>a polymerase used to extend a DNA chain. The four nucleotide<sup> </sup>triphosphates are sequentially flowed over the plate. An enzyme<sup> </sup>system is present in the buffer, which directs incorporation<sup> </sup>of pyrophosphate liberated by nucleotide addition into ATP,<sup> </sup>which then activates purified luciferase enzyme in the buffer<sup> </sup>to produce light. A CCD camera records each flash from each<sup> </sup>well on the plate. Sequential application of the four nucleotides<sup> </sup>allows DNA sequences of <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">100 bp to be built up <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">150 000 at a time<sup> </sup>(<a href="#B14">14</a>).<sup> </sup></p><p>

The initial sequence reaction, carried out on a single plate,<sup> </sup>yielded 135 528 sequence reads, of which 118 093 ultimately<sup> </sup>passed quality control. For the sequences to pass, we required<sup> </sup>that each have a perfect match to the bar code and primer region,<sup> </sup>and no more than one N in the determined sequence. A total of<sup> </sup>5.1% of the initial sequence reads had bar codes that were not<sup> </sup>included in the original experiment. The pyrosequencing method<sup> </sup>is error-prone at homopolymers, and of the incorrect bar codes,<sup> </sup>54% created homopolymeric sequences within the bar codes and<sup> </sup>were excluded on that basis. To suppress bar code &#8216;crossover&#8217;,<sup> </sup>the different viral samples were separated into separate quadrants<sup> </sup>of the sequencing plate as follows (numbers from <a href="#T1">Table 1</a>): samples<sup> </sup>1 and 2, quadrant 1; samples 3 and 5, quadrant 2; samples 6<sup> </sup>and 7, quadrant 3; sample 4, quadrant 4. Inspection of drug<sup> </sup>resistance calls for samples within the same quadrant showed<sup> </sup>no obvious bar code crossover.<sup> </sup></p><p>

For scoring drug resistance mutations, we used the Sierra Webservice<sup> </sup>at the HIV Drug Resistance Database at Stanford University (<a href="http://hivdb.stanford.edu/">http://hivdb.stanford.edu/</a>).<sup> </sup>To query the Drug Resistance Database, the pyrosequence reads<sup> </sup>were embedded in &#8216;dummy&#8217; HIV flanking sequences,<sup> </sup>and the resistance alleles identified over the sequenced region.<sup> </sup>To pass quality control at this step, we required that the full<sup> </sup>sequence be recognized as HIV by the HIV Drug Resistance database,<sup> </sup>and that all pyrosequence reads cover at least 60% of the genomic<sup> </sup>window interrogated. Resistance mutations called by the Stanford<sup> </sup>Database were filtered to match the International AIDS Society<sup> </sup>definitions.<sup> </sup></p><p>

<strong>Statistical analysis</strong><br>

Inspection of the raw counts of drug resistance calls in controls<sup> </sup>(Supplementary Table 2) showed that different positions showed<sup> </sup>differing error rates. For this reason, a statistical model<sup> </sup>was used that took into account the error rate measured at each<sup> </sup>position. The proportion of drug-resistant mutant calls in the<sup> </sup>combined HIV LAI DNA and HIV LAI RNA data sets were taken as<sup> </sup>the background error for each position. We took advantage of<sup> </sup>the Fisher's exact test to investigate whether drug resistance<sup> </sup>mutations were significantly enriched in the patient samples<sup> </sup>compared to controls. To control for multiple comparisons, a<sup> </sup>Bonferroni correction was applied. The <i>P</i>-values were multiplied<sup> </sup>by the number of comparisons within each individual (62 comparisons<sup> </sup>corresponding to 62 codons queried for drug resistance). Drug<sup> </sup>resistance calls with corrected <i>P</i>-values &lt;0.05 were judged<sup> </sup>to be significantly enriched. Statistical analysis was carried<sup> </sup>out in the <i>R</i> environment (<a href="http://www.r-project.org/">http://www.r-project.org/</a>).<sup> </sup></p><p>

<a name="SEC3"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
RESULTS
</font></th></tr></tbody></table>
<table align="right" border="1" cellpadding="5"><tbody><tr><th align="left"><font size="-1">
<a href="#top"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">TOP<br></a>
<a href="#ABS"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">ABSTRACT<br></a>
<a href="#SEC1"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">INTRODUCTION<br></a>
<a href="#SEC2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">MATERIALS AND METHODS<br></a>
<img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/dot.gif" border="0" height="9" hspace="5" width="11"><font color="#464c53">RESULTS</font><br>
<a href="#SEC4"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">DISCUSSION<br></a>
<a href="#SEC5"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">SUPPLEMENTARY DATA<br></a>
<a href="#BIBL"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

<strong>DNA bar coding and pyrosequencing</strong><br>

Primers were designed for amplifying the regions of HIV <i>pol</i><sup> </sup>that are known from previous work to be sites of substitutions<sup> </sup>that result in resistance to PR and RT inhibitors. Because the<sup> </sup>most useful design would allow amplification of HIV sequences<sup> </sup>from any of the viral subtypes, we designed &#8216;Pan-HIV&#8217;<sup> </sup>primers that would amplify subtypes A, B, C, D and 01_AE, the<sup> </sup>major subtypes circulating world-wide.<sup> </sup></p><p>

Typical read lengths for the pyrosequencing method at the time<sup> </sup>of this experiment were <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">100 bp. For the sequencing procedure,<sup> </sup>it is desirable to use fragments that are somewhat longer than<sup> </sup>this, to allow electrophoretic separation of the PCR products<sup> </sup>away from short contaminating sequences such as primer dimers.<sup> </sup>For this reason, we designed 11 overlapping amplicons, as shown<sup> </sup>in <a href="#F1">Figure 1</a>, to allow analysis of all known positions of PR<sup> </sup>and RT drug resistance mutations [cataloged by the International<sup> </sup>AIDS Society (Fall 2006 Revision) (<a href="#B18">18</a>)] while allowing purification<sup> </sup>of fragments in the 200&#8211;400 bp size range.<sup> </sup></p><p>

<a name="F1"><!-- null --></a>
<br clear="all"></p><center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
<a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F1"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/gkm435f1.gif" alt="Figure 1" border="2" height="72" hspace="10" vspace="5" width="200"></a><br>

<strong>View larger version</strong> (11K):<br>
<nobr><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F1">[in this window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/content-nw/full/gkm435v1/F1" onclick="startTarget('F1', 590, 358); this.href='/cgi/content-nw/full/gkm435v1/F1'" onmouseover="window.status='View figure in a separate window'; return true" target="F1">[in a new window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/powerpoint/gkm435v1/F1">[Download PowerPoint slide]</a><br>&nbsp;</nobr>
</td><td align="left" valign="top">
<b>Figure 1.</b> Amplicons querying positions of HIV drug resistance
mutations in the PR and RT-coding regions. The HIV genetic map is shown
at the top. Below is shown an expanded version of the segment of <i>pol</i>
encoding PR and part of RT. At the bottom is shown the location of the
amplicons used to interrogate positions of potential drug resistance
mutations.<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


<strong>Viral populations studied</strong><br>

A key consideration in analyzing our results was distinguishing<sup> </sup>authentic drug-resistant mutations from erroneous calls. After<sup> </sup>isolation of HIV RNA from particles, reverse transcription followed<sup> </sup>by PCR (RT-PCR) has the potential to introduce mutations. The<sup> </sup>pyrosequencing procedure, as implemented at 454 Life Sciences<sup> </sup>(<a href="#B14">14</a>), also requires a PCR amplification step, and the pyrosequencing<sup> </sup>method is more error prone than the Sanger method.<sup> </sup><p>

Several controls were therefore included in the experiment to<sup> </sup>allow estimation of the background error rate (<a href="#T1">Table 1</a>). Plasmid<sup> </sup>DNA from the HIV isolate LAI was used as template for PCR amplification<sup> </sup>by the 11 pan-HIV primers and the products analyzed. Because<sup> </sup>the HIV LAI DNA sequence is known, this serves as a control<sup> </sup>for error in the RT-PCR and pyrosequencing steps. RNA from HIV<sup> </sup>LAI viral particles was included as another control. This provided<sup> </sup>a second measure of error and also allowed us to assess the<sup> </sup>misincorporation rate due to transcription and reverse transcription<sup> </sup>of the HIV RNA, which proved to be undetectable using the methods<sup> </sup>described later.<sup> </sup></p><p>

As a test of the detection sensitivity, we studied RNA from<sup> </sup>particles of another strain, HIV NL4-3, which were &#8216;spiked&#8217;<sup> </sup>with one-twentieth the amount of a drug-resistant HIV NL4-3<sup> </sup>derivative containing five substitutions in the PR-coding region<sup> </sup>(encoding L10R/M46I/L63P/V82T/I84V). Viral stocks were normalized<sup> </sup>by measuring the amount of the p24 capsid protein in each stock<sup> </sup>by ELISA.<sup> </sup></p><p>

A fourth sample contained a pool of five HIV subtypes (A, B,<sup> </sup>C, D and 01<sub>AE</sub>) (<a href="#B19">19</a>), and was included to illustrate the ability<sup> </sup>of the pan-HIV primers to amplify sequences from all five, and<sup> </sup>the downstream bioinformatic methods to distinguish sequence<sup> </sup>data from each.<sup> </sup></p><p>

We also studied three samples of plasma from patients with drug-resistant<sup> </sup>HIV. For each of the three, we obtained standard diagnostic<sup> </sup>sequence data generated previously using the Viroseq HIV Genotyping<sup> </sup>System v 2.0 (Applied Biosystems, Foster City, CA, USA) and<sup> </sup>used in managing each patients&#8217; treatment. Analysis of<sup> </sup>these samples allowed us to compare the sensitivity of the pyrosequencing<sup> </sup>method to a standard method.<sup> </sup></p><p>

<strong>The DNA bar coding strategy</strong><br>

Since one of our goals was developing methods for testing many<sup> </sup>samples in single sequencing experiments, we developed a DNA<sup> </sup>bar coding strategy to allow sample multiplexing (<a href="#F2">Figure 2</a>).<sup> </sup>Each primer consisted of the 454 A and B sequences at the 5'<sup> </sup>ends, required for the emulsion PCR, and the HIV-complementary<sup> </sup>regions at the 3' end. To distinguish different amplicons in<sup> </sup>a pool, we added a 4 bp DNA bar code sequence between the 454<sup> </sup>A or B sequence and the HIV-complementary region. Because the<sup> </sup>454 sequencing method has an increased error rate at positions<sup> </sup>of adjacent nucleotides of the same type (homopolymers), we<sup> </sup>avoided using bar codes containing adjacent identical nucleotides.<sup> </sup></p><p>

<a name="F2"><!-- null --></a>
<br clear="all"></p><center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
<a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F2"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/gkm435f2.gif" alt="Figure 2" border="2" height="84" hspace="10" vspace="5" width="200"></a><br>

<strong>View larger version</strong> (11K):<br>
<nobr><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F2">[in this window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/content-nw/full/gkm435v1/F2" onclick="startTarget('F2', 590, 384); this.href='/cgi/content-nw/full/gkm435v1/F2'" onmouseover="window.status='View figure in a separate window'; return true" target="F2">[in a new window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/powerpoint/gkm435v1/F2">[Download PowerPoint slide]</a><br>&nbsp;</nobr>
</td><td align="left" valign="top">
<b>Figure 2.</b> The DNA bar coding system. Primers are shown
diagrammatically, illustrating the placement of the DNA bar code
between the 454 primers (<b>A</b> and <b>B</b>) and the
HIV-complementary sequences. An example of a primer sequence is shown
at the bottom. DNA 5' ends in the primers are shown as the black balls.<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


<strong>Sample amplification and initial sequence analysis</strong><br>

PCR amplification was carried out on the seven HIV nucleic acid<sup> </sup>templates listed in <a href="#T1">Table 1</a> using the pan-HIV primers. All amplification<sup> </sup>reactions yielded DNA chains of the expected length when analyzed<sup> </sup>by agarose gel electrophoresis and ethidium bromide staining.<sup> </sup><a href="#F3">Figure 3</a> shows a sample amplification of subtype C viral RNA.<sup> </sup>The PCR amplicons were then pooled and subjected to pyrosequencing<sup> </sup>using the method implemented by 454 Life Sciences (<a href="#B14">14</a>). Samples<sup> </sup>were attached to beads and amplified using emulsion PCR, the<sup> </sup>beads with bound DNA were applied to a picoliter plate, and<sup> </sup>sequences on beads were determined using the pyrosequencing<sup> </sup>method. A total of 135 528 sequence reads were returned, of<sup> </sup>average length 103 bp. After quality control, 118 093 sequences<sup> </sup>were available for analysis, corresponding to <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">12 million base<sup> </sup>pairs of DNA sequence. Of the seven bar codes used, the number<sup> </sup>of sequences returned per bar code after quality control ranged<sup> </sup>from 28 751 (pooled subtypes) to 7398 (NL4-3 with doped drug<sup> </sup>resistance allele). More of the PCR products from the subtype<sup> </sup>pool was used for sequencing because we expected a relatively<sup> </sup>higher level of diversity from this sample due to the diversity<sup> </sup>of the templates. Overall, 121 amplification products were pooled<sup> </sup>and analyzed, and sequences from all were recovered in good<sup> </sup>yield.<sup> </sup><p>

<a name="F3"><!-- null --></a>
<br clear="all"></p><center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
<a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F3"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/gkm435f3.gif" alt="Figure 3" border="2" height="92" hspace="10" vspace="5" width="200"></a><br>

<strong>View larger version</strong> (46K):<br>
<nobr><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F3">[in this window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/content-nw/full/gkm435v1/F3" onclick="startTarget('F3', 590, 402); this.href='/cgi/content-nw/full/gkm435v1/F3'" onmouseover="window.status='View figure in a separate window'; return true" target="F3">[in a new window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/powerpoint/gkm435v1/F3">[Download PowerPoint slide]</a><br>&nbsp;</nobr>
</td><td align="left" valign="top">
<b>Figure 3.</b> Amplification of HIV subtype C using the pan-HIV
primer set. The figure shows products of RT-PCR reactions analyzed by
agarose gel electrophoresis and ethidium bromide staining. The
amplicons extend from the 5' side of the PR-coding region (left) to an
internal region of the RT-coding region (right), thereby covering all
the known positions of drug resistance mutations in the PR and
RT-coding regions (primer sequences are in Supplementary Table 1). The
marker ladder has &#8216;steps&#8217; of 100 bp. The position of the 500 bp
fragment is marked.<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


We next sought to identify mutations within the HIV sequences<sup> </sup>expected to confer drug resistance. Sequences passing quality<sup> </sup>control were analyzed at the HIV Drug Resistance Database at<sup> </sup>Stanford University (<a href="http://hivdb.stanford.edu/">http://hivdb.stanford.edu/</a>) (<a href="#B17">17</a>), and the<sup> </sup>results tabulated. For our initial analysis, we restricted our<sup> </sup>attention to the best documented drug resistance mutations as<sup> </sup>summarized by the International AIDS Society Drug Resistance<sup> </sup>Mutations in HIV (Fall 2006 Revision) (<a href="#B2">2</a>). Overall, 62 positions<sup> </sup>of drug resistance were queried, and the frequency of drug resistance<sup> </sup>calls at each codon tabulated (raw data in Supplementary Table<sup> </sup>2).<sup> </sup><p>

The pool of HIV subtypes (<a href="#T1">Table 1</a>, sample 4) was separated into<sup> </sup>subtype-specific groups by aligning the sequences against subtype-specific<sup> </sup>consensus sequences. Sequences were recovered for all five subtypes<sup> </sup>in good yield. Supplementary Table 3 catalogs the sequences<sup> </sup>identified and the drug resistance mutations detected in each<sup> </sup>subtype, and Supplementary Table 4 presents the rate of polymorphism<sup> </sup>at sites not involved in drug resistance.<sup> </sup></p><p>

<strong>Statistical analysis</strong><br>

A statistical procedure was devised to allow detection of significant<sup> </sup>enrichment of drug resistance mutations above the error rate.<sup> </sup>Inspection of the control data (HIV LAI DNA and RNA templates)<sup> </sup>revealed that, of the 124 codons queried (62 codons in each<sup> </sup>of the two controls), 57/124 codons showed zero calls for drug<sup> </sup>resistance (Supplementary Table 2). All 62 control codons showed<sup> </sup>&lt;1% resistance calls. However, 4/124 positions showed erroneous<sup> </sup>calls for drug resistance between 0.5% and 1% of sequences.<sup> </sup>For this reason, a statistical procedure was devised to assess<sup> </sup>the possible presence of drug resistance mutations in the experimental<sup> </sup>samples in light of the position-specific error rate.<sup> </sup></p><p>

The proportion of drug resistance calls at each position in<sup> </sup>the controls (<a href="#T1">Table 1</a>, samples 1 and 2) was assessed and taken<sup> </sup>as the position-specific background. The frequency of resistance<sup> </sup>calls in each sample was then tested against the position-specific<sup> </sup>background using Fisher's exact test. Inspection of the initial<sup> </sup>collection of <i>P</i>-values showed that there were more positions<sup> </sup>of significant enrichment than expected in the controls (<a href="#T1">Table 1</a>,<sup> </sup>samples 1&#8211;3), which was not surprising because the large<sup> </sup>number of comparisons carried out (62 for each patient) increased<sup> </sup>the likelihood of obtaining significant enrichment by chance.<sup> </sup>To control for the inflation of error due to multiple comparisons,<sup> </sup>we applied a Bonferroni correction, in which the <i>P</i>-value from<sup> </sup>Fisher's exact test was multiplied by the number of comparisons<sup> </sup>in each patient (62). Thirty-six positions achieved significance<sup> </sup>after correction (<i>P</i> &lt; 0.05), and are shown as black tiles<sup> </sup>in <a href="#F4">Figure 4</a>.<sup> </sup></p><p>

<a name="F4"><!-- null --></a>
<br clear="all"></p><center><table cellpadding="0" cellspacing="0" width="95%"><tbody><tr bgcolor="#e1e1e1"><td><table cellpadding="2" cellspacing="2">
<tbody><tr bgcolor="#e1e1e1"><td align="center" bgcolor="#ffffff" valign="top">
<a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F4"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/gkm435f4.gif" alt="Figure 4" border="2" height="195" hspace="10" vspace="5" width="200"></a><br>

<strong>View larger version</strong> (28K):<br>
<nobr><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435v1/F4">[in this window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/content-nw/full/gkm435v1/F4" onclick="startTarget('F4', 590, 629); this.href='/cgi/content-nw/full/gkm435v1/F4'" onmouseover="window.status='View figure in a separate window'; return true" target="F4">[in a new window]</a><br>
<a href="http://nar.oxfordjournals.org/cgi/powerpoint/gkm435v1/F4">[Download PowerPoint slide]</a><br>&nbsp;</nobr>
</td><td align="left" valign="top">
<b>Figure 4.</b> Summary of the drug resistance alleles detected.
Results are shown for PR (top two grids) and RT (bottom two grids). The
seven HIV samples studied are labeled to the left of each grid. The
amino acid positions of drug-resistant mutations are marked at the top
of the grid, labeled DRM for drug resistance mutation. Black tiles in
the grid indicate positions that were significantly enriched for drug
resistance mutations in the pyrosequencing data after correction for
multiple comparisons. Raw counts are available in Supplementary Table
2. Black tiles with asterisks indicate positions that were enriched in
drug resistance mutations in the pyrosequencing data that were not
identified by a conventional genotyping method (Viroseq HIV Genotyping
System v 2.0). The &#8216;i&#8217; at RT position 69 denotes the insertions at this
position that are known to confer drug resistance.<p>


</p></td></tr></tbody></table>
</td></tr></tbody></table></center>&nbsp;<br>


Proper performance of this procedure could be verified by analyzing<sup> </sup>the results for the HIV NL4-3 sample spiked with 5% virions<sup> </sup>encoding the L10R/M46I/L63P/V82T/I84V resistance substitutions.<sup> </sup>All five doped drug resistance alleles were found to be significantly<sup> </sup>enriched after the correction for multiple comparisons, and<sup> </sup>no additional mutations were called erroneously (<a href="#F4">Figure 4</a>).<sup> </sup>The measured frequencies of the drug resistance alleles, initially<sup> </sup>added at 5%, were L10: 4.6%, M46: 1.3%, L63: 4.8%, V82: 2.9%,<sup> </sup>I84: 3.1%. We conclude that the pyrosequencing method together<sup> </sup>with the above statistical procedure is sensitive and accurate<sup> </sup>enough to selectively detect drug resistance substitutions present<sup> </sup>as 5% of the viral population.<sup> </sup><p>

<strong>Drug resistance alleles detected in patient samples</strong><br>

Drug resistance mutations were identified using pyrosequencing<sup> </sup>in the three patient samples (<a href="#T1">Table 1</a>, samples 5&#8211;7), and<sup> </sup>the calls compared to those called by the Viroseq HIV Genotyping<sup> </sup>System (analyzed using the HIV Drug Resistance Database at Stanford<sup> </sup>University). The pyrosequencing study identified all 15 of the<sup> </sup>drug-resistant mutations that were called using the Viroseq<sup> </sup>genotyping pipeline (<a href="#F4">Figure 4</a>, black bars without asterisks).<sup> </sup>The median proportion of mutations called by the Viroseq method<sup> </sup>was 88% drug resistance calls as measured in the pyrophosphate<sup> </sup>sequencing data (range: 28&#8211;99%). Four additional lower<sup> </sup>abundance drug resistance mutations were called in the pyrosequencing<sup> </sup>data that were not called by the Viroseq pipeline (<a href="#F4">Figure 4</a>,<sup> </sup>black bars with white asterisks), one for patient 1, one for<sup> </sup>patient 2 and two for patient 3 (<a href="#F4">Figure 4</a>, black bars with asterisks).<sup> </sup>The frequency of resistance mutations called by pyrosequencing<sup> </sup>only ranged from 11.6 to 0.65% of the total. A few positions<sup> </sup>were represented by many sequences, and appear to be just below<sup> </sup>the level of detection of the conventional genotyping assay.<sup> </sup>For example, the RT drug resistance substitution K70R was represented<sup> </sup>by 40 calls out of 305, and the RT mutation M184V was represented<sup> </sup>by 46 calls out of 726 (both from patient 3). At the other extreme,<sup> </sup>significant detection could be achieved by as few as nine drug<sup> </sup>resistance calls for codons in cases where the background was<sup> </sup>low&#8212;for the M46 position in patient 1, drug resistance<sup> </sup>for 9 out of 1377 calls achieved significance in the presence<sup> </sup>of a background of 1 out of 2395 calls (<i>P</i> = 0.0014, Fisher's<sup> </sup>exact test, two-sided comparison). The potential clinical significance<sup> </sup>of the minor drug-resistant alleles is discussed later.<sup> </sup></p><p>

Eight resistance mutations were also identified in the collection<sup> </sup>of sequences from different HIV subtypes (<a href="#T1">Table 1</a>, sample 4,<sup> </sup>data summarized in Supplementary Table 3). The HIV samples studied<sup> </sup>were isolated from patients worldwide in 1991 (<a href="#B19">19</a>). The subtype<sup> </sup>B sample was isolated in the United States, subtypes A, C and<sup> </sup>D in Uganda, and subtype 01_AE in Thailand. None of the patients<sup> </sup>were on antiretroviral therapy at the time of collection. Eight<sup> </sup>drug resistance mutations were identified in the PR-coding region,<sup> </sup>and none in RT. In some cases the resistance mutations were<sup> </sup>present as substantial fractions of the populations, such as<sup> </sup>the M36I substitution in subtype D, which comprises more than<sup> </sup>78%. Others were less common, comprising <img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/sim.gif" alt="~" border="0">20% of the population.<sup> </sup>It is uncertain how many of these mutations, which appear to<sup> </sup>be pre-existing polymorphisms, would influence sensitivity to<sup> </sup>protease inhibitors (<a href="#B20">20</a>,<a href="#B21">21</a>). Taken together, these findings<sup> </sup>demonstrate the ability of the pyrosequencing method to identify<sup> </sup>minor drug resistance mutations in individuals infected with<sup> </sup>diverse HIV subtypes.<sup> </sup></p><p>

<a name="SEC4"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
DISCUSSION
</font></th></tr></tbody></table>
<table align="right" border="1" cellpadding="5"><tbody><tr><th align="left"><font size="-1">
<a href="#top"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">TOP<br></a>
<a href="#ABS"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">ABSTRACT<br></a>
<a href="#SEC1"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">INTRODUCTION<br></a>
<a href="#SEC2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">MATERIALS AND METHODS<br></a>
<a href="#SEC3"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">RESULTS<br></a>
<img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/dot.gif" border="0" height="9" hspace="5" width="11"><font color="#464c53">DISCUSSION</font><br>
<a href="#SEC5"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">SUPPLEMENTARY DATA<br></a>
<a href="#BIBL"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

Here we describe the use of DNA bar coding and pyrosequencing<sup> </sup>in detecting minor drug resistance mutations in HIV populations.<sup> </sup>We used pyrosequencing to generate 118 093 sequence reads from<sup> </sup>the <i>pol</i> region of seven samples of viral populations or controls.<sup> </sup>The seven samples were analyzed in a single sequencing experiment,<sup> </sup>made possible by use of DNA bar coding to distinguish the different<sup> </sup>samples. As controls we analyzed a DNA plasmid encoding HIV<sup> </sup>LAI and HIV LAI RNA from viral particles, allowing an empirical<sup> </sup>estimation of error at each codon at risk for mutation to drug<sup> </sup>resistance. To test the assay sensitivity, we analyzed a mixture<sup> </sup>containing HIV NL4-3 wild-type virions mixed with 5% of mutant<sup> </sup>virions containing five drug resistance mutations. All five<sup> </sup>mutations were called as present in the mixture without false<sup> </sup>positives, demonstrating the accuracy of the method. Analysis<sup> </sup>of viral populations from three patients harboring drug-resistant<sup> </sup>HIV revealed all the mutations called by the conventional genotyping<sup> </sup>method (Viroseq), plus four additional less abundant drug resistance<sup> </sup>mutations comprising from 11.6% to 0.65% of the population.<sup> </sup></p><p>

Previously several methods have been reported for sensitive<sup> </sup>detection of rare drug-resistant mutations, some with impressive<sup> </sup>sensitivity (<a href="#B10">10</a>,<a href="#B11">11</a>). However, only the combination of DNA bar<sup> </sup>coding and pyrosequencing offers the opportunity to determine<sup> </sup>the full sequence of genomic regions with drug-resistant mutations<sup> </sup>from many samples in a single sequencing experiment. Using this<sup> </sup>method, sequence polymorphisms that were not specifically targeted<sup> </sup>for analysis can be identified and analyzed for possible correlations<sup> </sup>with drug resistance, which is not possible with most of the<sup> </sup>alternative methods. Here we analyzed seven viral populations<sup> </sup>in a single picoliter sequencing plate, but there is no reason<sup> </sup>that the number could not be much larger. In another study,<sup> </sup>we have successfully sequenced 42 different DNA bar codes in<sup> </sup>a single plate (unpublished data), indicating the potential.<sup> </sup></p><p>

Several of the low abundance drug resistance mutations detected<sup> </sup>here are of potential clinical significance, since they may<sup> </sup>confer reduced sensitivity to drugs that otherwise might seem<sup> </sup>attractive for therapy. For example, patient 3 was found to<sup> </sup>harbor low level resistance alleles in RT at K70 and M184, which<sup> </sup>would be likely to impair therapy with several of the NRTIs,<sup> </sup>though not with all NRTIs. Patient 3 had been treated with NRTIs<sup> </sup>known to elicit these mutations, probably explaining their presence.<sup> </sup>Because alternative NRTIs are available for which all of the<sup> </sup>patient 3 viruses would remain sensitive, knowledge of the minor<sup> </sup>alleles could have improved the ability to choose effective<sup> </sup>therapy in this case. Looking forward, it will be important<sup> </sup>to test more fully the importance of minor HIV drug-resistant<sup> </sup>populations on antiretroviral responses and the impact of such<sup> </sup>information on treatment outcomes.<sup> </sup></p><p>

Lastly, the methods described here may be useful in implementing<sup> </sup>drug resistance genotyping in resource-limited settings. Using<sup> </sup>the DNA bar coding strategy, it should be possible to multiplex<sup> </sup>large numbers of patient samples in single sequencing runs,<sup> </sup>thereby driving down costs. Though many logistical obstacles<sup> </sup>would need to be overcome, the combination of DNA bar coding<sup> </sup>and pyrosequencing offers a prototype technology for affordable<sup> </sup>HIV genotyping.<sup> </sup></p><p>

<a name="SEC5"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
SUPPLEMENTARY DATA
</font></th></tr></tbody></table>
<table align="right" border="1" cellpadding="5"><tbody><tr><th align="left"><font size="-1">
<a href="#top"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">TOP<br></a>
<a href="#ABS"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">ABSTRACT<br></a>
<a href="#SEC1"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">INTRODUCTION<br></a>
<a href="#SEC2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">MATERIALS AND METHODS<br></a>
<a href="#SEC3"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">RESULTS<br></a>
<a href="#SEC4"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">DISCUSSION<br></a>
<img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/dot.gif" border="0" height="9" hspace="5" width="11"><font color="#464c53">SUPPLEMENTARY DATA</font><br>
<a href="#BIBL"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/darrow.gif" border="0" height="9" hspace="5" width="11">REFERENCES<br></a>
</font></th></tr></tbody></table>
&nbsp;<br>

Supplementary Data are available at NAR Online.<sup> </sup></p><p>


<a name="ACK"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
ACKNOWLEDGEMENTS
</font></th></tr></tbody></table>
&nbsp;<br>

We thank Sridhar Hannenhalli and Rob Knight for helpful discussions,<sup> </sup>Rick Hodinka for high-throughput isolation of viral RNA, Heather<sup> </sup>Marshall for the purified HIV LAI particles and Tommy Lu and<sup> </sup>the creators of the Stanford HIV Database for allowing us to<sup> </sup>use their resource. This work was supported by the University<sup> </sup>of Pennsylvania. We also thank the AIDS Reagent Repository for<sup> </sup>HIV stocks. Funding to pay the Open Access publication charges<sup> </sup>for this article was provided by The University of Pennsylvania.<sup> </sup></p><p>

<i>Conflict of interest statement</i>. None declared.<sup> </sup></p><p>



<a name="BIBL"><!-- null --></a>
<br clear="right"><table bgcolor="#e1e1e1" cellpadding="0" cellspacing="0" width="100%">
 <tbody><tr><td align="left" bgcolor="#ffffff" valign="middle" width="5%"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/rarrow.gif" height="21" hspace="5" width="10"></td>
 <th align="left" valign="middle" width="95%"><font size="+2">&nbsp;&nbsp;
REFERENCES
</font></th></tr></tbody></table>
<table align="right" border="1" cellpadding="5"><tbody><tr><th align="left"><font size="-1">
<a href="#top"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">TOP<br></a>
<a href="#ABS"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">ABSTRACT<br></a>
<a href="#SEC1"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">INTRODUCTION<br></a>
<a href="#SEC2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">MATERIALS AND METHODS<br></a>
<a href="#SEC3"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">RESULTS<br></a>
<a href="#SEC4"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">DISCUSSION<br></a>
<a href="#SEC5"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/uarrow.gif" border="0" height="9" hspace="5" width="11">SUPPLEMENTARY DATA<br></a>
<img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/dot.gif" border="0" height="9" hspace="5" width="11"><font color="#464c53">REFERENCES</font><br>
</font></th></tr></tbody></table>
&nbsp;<br>

</p><ol compact="compact">
<a name="B1"><!-- null --></a><li value="1"> Clavel F, Hance AJ. HIV drug resistance. See comment. N. Engl. J. Med. (2004) 350:1023&#8211;1035.<!-- HIGHWIRE ID="0:2007:gkm435v1:1" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=FULL&amp;journalCode=nejm&amp;resid=350/10/1023"><nobr>[<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B2"><!-- null --></a></p></li><li value="2">
Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF,
Bozzette SA. The prevalence of antiretroviral drug resistance in the
United States. AIDS (2004) 18:1393&#8211;1401.<!-- HIGHWIRE ID="0:2007:gkm435v1:2" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1097%2F01.aids.0000131310.52526.c7&amp;link_type=DOI">[CrossRef]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=000222641500005&amp;link_type=ISI">[ISI]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=15199315&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B3"><!-- null --></a></p></li><li value="3">
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup
RA, Mellors JW, Connick E, et al. Antiretroviral-drug resistance among
patients recently infected with HIV. N. Engl. J. Med. (2002)
347:385&#8211;394.<!-- HIGHWIRE ID="0:2007:gkm435v1:3" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=nejm&amp;resid=347/6/385"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B4"><!-- null --></a></p></li><li value="4">
Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y, Richman D, Little
S. Clinical utility of HIV standard genotyping among
antiretroviral-naive individuals with unknown duration of infection.
Clin. Infect. Dis. (2007) 44:456&#8211;458.<!-- HIGHWIRE ID="0:2007:gkm435v1:4" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1086%2F510748&amp;link_type=DOI">[CrossRef]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=000243315100032&amp;link_type=ISI">[ISI]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=17205459&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B5"><!-- null --></a></p></li><li value="5">
Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A,
Pillay D, Porter K, et al. Time trends in primary resistance to HIV
drugs in the United Kingdom: multicentre observational study. See
comment. Br. Med. J. (2005) 331:1368.<!-- HIGHWIRE ID="0:2007:gkm435v1:5" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=331/7529/1368"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B6"><!-- null --></a></p></li><li value="6">
Mellors J, Palmer S, Nissley D, Kearny M, Halvas E, Bixby C, Demeter L,
Eshleman S, Bennett K, Hart S, Vaida F, Wantman M, Coffin J, Hammer S.
Low-frequency NNRTI-resistant variants contribute to failure of
efavirenz-containing regimen. (2004) Program and Abstracts of the 11th
Conference on Retroviruses and Opportunistic Infections Abstract 39.<!-- HIGHWIRE ID="0:2007:gkm435v1:6" --><!-- /HIGHWIRE --><p><a name="B7"><!-- null --></a></p></li><li value="7">
Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock
D, Falloon J, Davey R.T. Jr, et al. Multiple, linked human
immunodeficiency virus type 1 drug resistance mutations in
treatment-experienced patients are missed by standard genotype
analysis. J. Clin. Microbiol. (2005) 43:406&#8211;413.<!-- HIGHWIRE ID="0:2007:gkm435v1:7" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jcm&amp;resid=43/1/406"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B8"><!-- null --></a></p></li><li value="8">
Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong
P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, et al.
Intrapartum exposure to nevirapine and subsequent maternal responses to
nevirapine-based antiretroviral therapy. See comment. N. Engl. J. Med.
(2004) 351:229&#8211;240.<!-- HIGHWIRE ID="0:2007:gkm435v1:8" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=nejm&amp;resid=351/3/229"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B9"><!-- null --></a></p></li><li value="9">
Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand
F, Makhema J, Moffat C, et al. Response to antiretroviral therapy after
a single, peripartum dose of nevirapine. N. Engl. J. Med. (2007)
356:135&#8211;147.<!-- HIGHWIRE ID="0:2007:gkm435v1:9" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=nejm&amp;resid=356/2/135"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B10"><!-- null --></a></p></li><li value="10">
Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM,
Frenkel LM, Hazelwood JD, Johnson VA, et al. Blinded, multicenter
comparison of methods to detect a drug-resistant mutant of human
immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol.
(2006) 44:2612&#8211;2614.<!-- HIGHWIRE ID="0:2007:gkm435v1:10" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jcm&amp;resid=44/7/2612"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B11"><!-- null --></a></p></li><li value="11">
Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F. Detection of minor
drug-resistant populations by parallel allele-specific sequencing. Nat.
Methods (2007) 4:123&#8211;125.<!-- HIGHWIRE ID="0:2007:gkm435v1:11" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1038%2Fnmeth995&amp;link_type=DOI">[CrossRef]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=000243998100010&amp;link_type=ISI">[ISI]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=17206150&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B12"><!-- null --></a></p></li><li value="12">
Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD,
Morris D, Hubbell E, et al. Extensive polymorphisms observed in HIV-1
clade B protease gene using high-density oligonucleotide arrays. Nat.
Med. (1996) 2:753&#8211;759.<!-- HIGHWIRE ID="0:2007:gkm435v1:12" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1038%2Fnm0796-753&amp;link_type=DOI">[CrossRef]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=A1996UU68000030&amp;link_type=ISI">[ISI]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=8673920&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B13"><!-- null --></a></p></li><li value="13">
O&#8217;Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J.
Monitoring resistance to human immunodeficiency virus type 1 protease
inhibitors by pyrosequencing. J. Clin. Microbiol. (2001) 39:464&#8211;473.<!-- HIGHWIRE ID="0:2007:gkm435v1:13" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jcm&amp;resid=39/2/464"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B14"><!-- null --></a></p></li><li value="14">
Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka
J, Braverman MS, Chen YJ, et al. Genome sequencing in microfabricated
high-density picolitre reactors. Nature (2005) 437:376&#8211;380.<!-- HIGHWIRE ID="0:2007:gkm435v1:14" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=16056220&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B15"><!-- null --></a></p></li><li value="15">
Binladen J, Gilbert MT, Bollback JP, Panitz F, Bendixen C, Nielsen R,
Willerslev E. The use of coded PCR primers enables high-throughput
sequencing of multiple homolog amplification products by 454 parallel
sequencing. PLoS ONE (2007) 2:e197.<!-- HIGHWIRE ID="0:2007:gkm435v1:15" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1371%2Fjournal.pone.0000197&amp;link_type=DOI">[CrossRef]</a><!-- /HIGHWIRE --><p><a name="B16"><!-- null --></a></p></li><li value="16">
Shoemaker DD, Lashkari DA, Morris D, Mittmann M, Davis RW. Quantitative
phenotypic analysis of yeast deletion mutants using a highly parallel
molecular bar-coding strategy. Nat. Genet. (1996) 14:450&#8211;456.<!-- HIGHWIRE ID="0:2007:gkm435v1:16" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1038%2Fng1296-450&amp;link_type=DOI">[CrossRef]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=A1996VV73000021&amp;link_type=ISI">[ISI]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=8944025&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B17"><!-- null --></a></p></li><li value="17">
Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human
immunodeficiency virus reverse transcriptase and protease sequence
database. Nucleic Acids Res. (2003) 31:298&#8211;303.<!-- HIGHWIRE ID="0:2007:gkm435v1:17" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=nar&amp;resid=31/1/298"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B18"><!-- null --></a></p></li><li value="18">
Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D,
Schapiro JM, Telenti A, Richman DD. Update of the drug resistance
mutations in HIV-1: Fall 2005. Top. HIV Med. (2005) 13:125&#8211;131.<!-- HIGHWIRE ID="0:2007:gkm435v1:18" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=16304457&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B19"><!-- null --></a></p></li><li value="19">
Jagodzinski LL, Wiggins DL, McManis JL, Emery S, Overbaugh J, Robb M,
Bodrug S, Michael NL. Use of calibrated viral load standards for group
M subtypes of human immunodeficiency virus type 1 to assess the
performance of viral RNA quantitation tests. J. Clin. Microbiol. (2000)
38:1247&#8211;1249.<!-- HIGHWIRE ID="0:2007:gkm435v1:19" --><a href="http://nar.oxfordjournals.org/cgi/ijlink?linkType=ABST&amp;journalCode=jcm&amp;resid=38/3/1247"><nobr>[Abstract/<font color="#cc0000">Free</font>&nbsp;Full&nbsp;Text]</nobr></a><!-- /HIGHWIRE --><p><a name="B20"><!-- null --></a></p></li><li value="20"> Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J. Clin. Virol. (2004) 29:152&#8211;159.<!-- HIGHWIRE ID="0:2007:gkm435v1:20" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1016%2FS1386-6532%2803%2900115-X&amp;link_type=DOI">[CrossRef]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=000189219300002&amp;link_type=ISI">[ISI]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=14962783&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p><a name="B21"><!-- null --></a></p></li><li value="21">
Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V. Impact of frequent
natural polymorphisms at the protease gene on the in vitro
susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin.
Virol. (2004) 31:215&#8211;220.<!-- HIGHWIRE ID="0:2007:gkm435v1:21" --><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=10.1016%2Fj.jcv.2004.03.015&amp;link_type=DOI">[CrossRef]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=000225028100008&amp;link_type=ISI">[ISI]</a><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=15465415&amp;link_type=MED">[Medline]</a><!-- /HIGHWIRE --><p></p></li></ol>


		
        
        
	
	
	
	
	




 

<img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" alt=" " height="30" width="0"><br><a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=CITEULIKE" style="text-decoration: none; font-size: smaller;" title="CiteULike"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/citeulike.gif" alt="Add to CiteULike" border="0"> CiteULike</a>&nbsp;&nbsp;&nbsp;<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=CONNOTEA" style="text-decoration: none; font-size: smaller;" title="Connotea"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/connotea.gif" alt="Add to Connotea" border="0"> Connotea</a>&nbsp;&nbsp;&nbsp;<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=DEL_ICIO_US" style="text-decoration: none; font-size: smaller;" title="Del.icio.us"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/delicious.gif" alt="Add to Del.icio.us" border="0"> Del.icio.us</a>&nbsp;&nbsp;&nbsp; <a href="http://nar.oxfordjournals.org/help/social_bookmarks.dtl" style="font-size: smaller;">What's this?</a>








<br clear="all">




  <font face="">
  
  </font>
<br clear="all">
<br clear="all">






	
	
	

<a name="otherarticles"><!-- null --></a>



<p><font size="+2"><strong>
This article has been cited by other articles:</strong></font> 


</p><p>


	
		
 
 
 <table border="0" cellpadding="0" cellspacing="0" width="600">
 
 <tbody><tr bgcolor="#d9d4c5">
 
 
  <td align="center" valign="top" width="25"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="25"><br>
   
  </td>
 
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 
 <td align="center" nowrap="nowrap" valign="top" width="61">
 	<a href="http://www.pnas.org/"><img alt="Home page" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/search_result.gif" border="1" height="80" vspace="5" width="59"></a><br>
 </td>
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 <td nowrap="nowrap" valign="top" width="499">
 <a href="http://www.pnas.org/"><img alt="Proc. Natl. Acad. Sci. USA" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/pnas.gif" border="0" height="16" vspace="5" width="450"><img alt="Home page" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/homelink.gif" border="0" height="16" vspace="5" width="49"></a><br>
 <font face="verdana,arial,helvetica" size="-1">
P. J. Campbell, E. D. Pleasance, P. J. Stephens, E. Dicks, R. Rance, I.
Goodhead, G. A. Follows, A. R. Green, P. A. Futreal, and M. R. Stratton<br>
	<strong>Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing</strong><br>
	
		
			PNAS,
		
	
        
        September&nbsp;2,&nbsp;2008;
	105(35):
	13081 - 13086.
<br>
<a href="http://www.pnas.org/cgi/content/abstract/105/35/13081">[Abstract]</a>

<a href="http://www.pnas.org/cgi/content/full/105/35/13081">[Full Text]</a>
<a href="http://www.pnas.org/cgi/reprint/105/35/13081">[PDF]</a>
<br><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="499">
 </font></td>
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 </tr>
 <tr><td colspan="6"><hr align="left" color="#828282" noshade="noshade" size="1" width="600"></td></tr>
</tbody></table>

	
		
 
 
 <table border="0" cellpadding="0" cellspacing="0" width="600">
 
 <tbody><tr bgcolor="#d9d4c5">
 
 
  <td align="center" valign="top" width="25"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="25"><br>
   
  </td>
 
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 
 <td align="center" nowrap="nowrap" valign="top" width="61">
 	<a href="http://nar.oxfordjournals.org/"><img alt="Home page" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/search_result_002.gif" border="1" height="80" vspace="5" width="59"></a><br>
 </td>
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 <td nowrap="nowrap" valign="top" width="499">
 <a href="http://nar.oxfordjournals.org/"><img alt="Nucleic Acids Res" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/nar.gif" border="0" height="16" vspace="5" width="450"><img alt="Home page" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/homelink.gif" border="0" height="16" vspace="5" width="49"></a><br>
 <font face="verdana,arial,helvetica" size="-1">
G. P. Wang, A. Garrigue, A. Ciuffi, K. Ronen, J. Leipzig, C. Berry, C.
Lagresle-Peyrou, F. Benjelloun, S. Hacein-Bey-Abina, A. Fischer, <em>et al.</em><br>
	<strong>DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer</strong><br>
	
		
			Nucleic Acids Res.,
		
	
        
        May&nbsp;1,&nbsp;2008;
	36(9):
	e49 - e49.
<br>
<a href="http://nar.oxfordjournals.org/cgi/content/abstract/36/9/e49">[Abstract]</a>

<a href="http://nar.oxfordjournals.org/cgi/content/full/36/9/e49">[Full Text]</a>
<a href="http://nar.oxfordjournals.org/cgi/reprint/36/9/e49">[PDF]</a>
<br><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="499">
 </font></td>
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 </tr>
 <tr><td colspan="6"><hr align="left" color="#828282" noshade="noshade" size="1" width="600"></td></tr>
</tbody></table>

	
		
 
 
 <table border="0" cellpadding="0" cellspacing="0" width="600">
 
 <tbody><tr bgcolor="#d9d4c5">
 
 
  <td align="center" valign="top" width="25"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="25"><br>
   
  </td>
 
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 
 <td align="center" nowrap="nowrap" valign="top" width="61">
 	<a href="http://nar.oxfordjournals.org/"><img alt="Home page" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/search_result_002.gif" border="1" height="80" vspace="5" width="59"></a><br>
 </td>
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 <td nowrap="nowrap" valign="top" width="499">
 <a href="http://nar.oxfordjournals.org/"><img alt="Nucleic Acids Res" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/nar.gif" border="0" height="16" vspace="5" width="450"><img alt="Home page" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/homelink.gif" border="0" height="16" vspace="5" width="49"></a><br>
 <font face="verdana,arial,helvetica" size="-1">
	M. B. Noyes, X. Meng, A. Wakabayashi, S. Sinha, M. H. Brodsky, and S. A. Wolfe<br>
	<strong>A systematic characterization of factors that regulate Drosophila segmentation via a bacterial one-hybrid system</strong><br>
	
		
			Nucleic Acids Res.,
		
	
        
        May&nbsp;1,&nbsp;2008;
	36(8):
	2547 - 2560.
<br>
<a href="http://nar.oxfordjournals.org/cgi/content/abstract/36/8/2547">[Abstract]</a>

<a href="http://nar.oxfordjournals.org/cgi/content/full/36/8/2547">[Full Text]</a>
<a href="http://nar.oxfordjournals.org/cgi/reprint/36/8/2547">[PDF]</a>
<br><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="499">
 </font></td>
 <td width="5"><img alt="" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="5" width="5"></td>
 </tr>
 <tr><td colspan="6"><hr align="left" color="#828282" noshade="noshade" size="1" width="600"></td></tr>
</tbody></table>

	










<br clear="all">


	
	 
		
		
		  
			
	
		<table class="content_box_outer_table" align="right">
		
		
			<tbody><tr>
			<td>
		
	

<!-- beginning of inner table -->
	<table class="content_box_inner_table">
<!-- citation -->

	
		




	

	

	
		
			
<tbody><tr><td class="content_box_title_highlight" colspan="2">This Article</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
				
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				
					
				
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/abstract/gkm435v1">
				Abstract</a></strong>
				
					 						<img alt="Freely available" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/free.gif" border="0" height="7" width="32">
					
				
	
				</td></tr>
			
		
		
	

	
	
	

	
	
	


	
	
	

	
	
	

	
	
	
	
	
	
	
	
	

	
		
		
	
	
		
	

	

	
		
			
		
	

	

	
	 

	
	 

		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		<strong>
		
		
		
			<a href="http://nar.oxfordjournals.org/cgi/reprint/gkm435v1">
		Print PDF (173K) <img alt="Freely available" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/free.gif" border="0" height="7" width="32"> </a>

 
		
		</strong>
		</td></tr>
	
	

	
	
	
	
	

	
	
	

	
	


 
	 

		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		<strong>
		
		
			<a href="http://nar.oxfordjournals.org/cgi/screenpdf/gkm435v1">
		Screen PDF (175K) <img alt="Freely available" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/free.gif" border="0" height="7" width="32"> </a> 
		
		</strong>
		</td></tr>
	



	
		

	
		

	
		
		

			


	

			

			
		
	

			
	  
	

			

			
			

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435/DC1">
				Supplementary Material</a></strong>
			</td></tr>
			

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435/DC2">
				Supplementary Data</a></strong>
			</td></tr>
			

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/content/full/gkm435/DC3">
				Supplementary Data</a></strong>
			</td></tr>
			
			

			
	
	

	
		
	









	
		
	
		
		
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item"><font class="openaccess"><font class="openaccess_oa"><font class="openaccess_open">O</font><font class="openaccess_access">A</font></font></font><strong>
			All Versions of this Article:<br>
		
			<a href="http://nar.oxfordjournals.org/cgi/content/short/35/13/e91">
					35/13/e91</a>
			
		&nbsp;&nbsp;&nbsp;<font color="#000e4f"><em>most recent</em></font><br>
	

	
		
		
			
					gkm435v1
				
		</strong></td></tr>
	

	





	
	
	

	
		
	

	 

	
	
		  
    

	
	
	
	







		
	
		
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;saveAlert=no&amp;cited_by_criteria_resid=nar;gkm435v1&amp;return_type=article&amp;return_url=http%3A%2F%2Fnar.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2Fgkm435v1">
				Alert me when this article is cited</a></strong>
			</td></tr>
	

		
		

		
		
			
		

		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;saveAlert=no&amp;correction_criteria_value=gkm435v1&amp;return_type=article&amp;return_url=http%3A%2F%2Fnar.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2Fgkm435v1">
				Alert me if a correction is posted</a></strong>
			</td></tr>
		
























			
		
	

			
			
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">Services</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/mailafriend?url=http%3A%2F%2Fnar.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2Fgkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations">
				Email this article to a friend</a></strong>
			</td></tr>
			
			


	

	

	

		
		



			
			
			
		
	

		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		<strong>
		<a href="http://nar.oxfordjournals.org/cgi/search?qbe=nar;gkm435&amp;journalcode=nar&amp;minscore=5000">
		Similar articles in this journal</a>
		</strong>
		</td></tr>

		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=17576693&amp;link_type=MED_NBRS">
				Similar articles in PubMed</a></strong>
			</td></tr>
		
	


		



			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/alerts/etoc">
				Alert me to new issues of the journal</a></strong>
			</td></tr>
		

		
		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=nar;gkm435v1">
				Add to My Personal Archive</a></strong>
			</td></tr>
		
		
	

		
		
		

			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
			<strong><a href="http://nar.oxfordjournals.org/cgi/citmgr?gca=nar;gkm435v1">
			Download to citation manager</a></strong>
			</td></tr>
		
		
	


	
		
	

	



  			
		

	
	
	
	
	



	


		

		

	
	
	
		


	

	
	

	
		
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
			<strong><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org%2Fjnls%2Flist%2Fnar%2Fspecial%2F18%2Fdefault.html">Commercial Re-use Guidelines<br>for Open Access NAR Content </a></strong>
		</td></tr>
	
	

	

	















	
		
			
				
				
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">Google Scholar</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AC.+author%3AHoffmann%22">
							Articles by Hoffmann, C.</a></strong>
						</td></tr>
				
				
			
				
			
				
			
				
			
				
			
				
			
				
				

						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://scholar.google.com/scholar?q=%22author%3AF.%20D.+author%3ABushman%22">
							Articles by Bushman, F. D.</a></strong>
						</td></tr>
				
				
			
		
		
	
	
	
		
	
	

		
			
				
					
						
						
						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=http://nar.oxfordjournals.org/cgi/content/abstract/gkm435v1&amp;link_type=GOOGLESCHOLARRELATED">Search for Related Content</a></strong>
						</td></tr>		
						
				
			
		
	










	





	
		
<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">PubMed</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
			
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
				<strong><a href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=17576693&amp;link_type=PUBMED">
				PubMed Citation</a></strong>
			</td></tr>
		
	

	
		
		
			
				

						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=Hoffmann+C&amp;link_type=AUTHORSEARCH">
							Articles by Hoffmann, C.</a></strong>
						</td></tr>
				
			
				

						
		<tr><td class="content_box_arrow" valign="top" width="4"><img alt="Right arrow" src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/arrowTtrim.gif" border="0" height="11" width="4"></td><td class="content_box_item">
							<strong><a target="_blank" href="http://nar.oxfordjournals.org/cgi/external_ref?access_num=Bushman+FD&amp;link_type=AUTHORSEARCH">
							Articles by Bushman, F. D.</a></strong>
						</td></tr>
				
			
		

		
	

	
















	















	


































	
		

	

		
			
		
	 
		











	

	








	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr><tr><td class="content_box_title" colspan="2">Social Bookmarking</td></tr>
	<tr><td class="content_box_space_between_sections" colspan="2"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" height="1" width="200"></td></tr>
	<tr><td class="content_box_arrow"><img alt=" " src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/spacer.gif" border="0" height="11" width="4"></td><td class="content_box_item">
		
			
			<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=CITEULIKE" title="CiteULike"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/citeulike.gif" alt="Add to CiteULike" border="0"></a>&nbsp;&nbsp;
			
		
			
		
			
			<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=CONNOTEA" title="Connotea"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/connotea.gif" alt="Add to Connotea" border="0"></a>&nbsp;&nbsp;
			
		
			
			<a href="http://nar.oxfordjournals.org/cgi/external_ref?tag_url=http://nar.oxfordjournals.org/cgi/content/long/gkm435v1&amp;title=DNA+bar+coding+and+pyrosequencing+to+identify+rare+HIV+drug+resistance+mutations+--+Hoffmann+et+al.+0+%282007%29%3A+gkm435v1+--+Nucl.+Acids+Res.&amp;doi=10.1093/nar/gkm435&amp;link_type=DEL_ICIO_US" title="Del.icio.us"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/delicious.gif" alt="Add to Del.icio.us" border="0"></a>&nbsp;&nbsp;
			
		
			
		
			
		
			
		
			
		
		<br><a href="http://www.oxfordjournals.org/help/features/index.html#socialbookmarking">What's this?</a>
	</td></tr>































	</tbody></table>
</td></tr></tbody></table> 


					
					
	

<br clear="all">








	
</p></div>
<!-- /footer.mc begins -->
</div>
<!-- OAS AD 'Bottom' begin -->
<div id="oas_bottom">
<script type="text/javascript">
<!--
OAS_AD('Bottom');
//-->
</script><a href="http://oas.oxfordjournals.org/RealMedia/ads/click_lx.ads/nar.oxfordjournals.org/cgi/content/full/gkm435v1/L34/1437524072/Bottom/OxfordJournals/H_AllJrnlsDevC_OJ_ANY_26NOV08_AJ/developing-countires-728x90.gif/6761755769456b3171746f4141434947?x" target="_top"><img src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/developing-countires-728x90.gif" alt="DEVELOPING COUNTRIES: free and reduced rate access" border="0" height="90" width="728"></a>
</div>
<!--OAS AD'Bottom'end -->

<div id="secondary_footer">
<div id="issn">
Online ISSN 1362-4962 - Print ISSN 0305-1048</div>
<div id="copyright">
<a href="http://nar.oxfordjournals.org/misc/terms.dtl">Copyright ©</a> 2008 Oxford University Press</div>
<div id="inst_logo"></div>
</div>
<div id="primary_footer">
<div id="site_logo">
<strong><span>Oxford Journals</span></strong>
<em><span>Oxford University Press</span></em>
</div>
<div id="third_nav">
<ul>
<li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
<!-- <li><a href="http://www.oxfordjournals.org/terms_conditions.html">Terms &amp; Conditions</a></li> -->
<li><a href="http://www.oup.co.uk/privacy/">Privacy Policy</a></li>
<li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
</ul>
</div>
<div id="other_oup_sites">
<form action="http://www.oxfordjournals.org/service/redirect">
<div>
<label for="site_list">Other Oxford University Press sites:</label>
<select name="url" id="site_list">
<option value="http://www.oup.com/">Oxford University Press</option>
<option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
<option value="http://www.anb.org/">American National Biography</option>
<option value="http://www.oup.co.uk/booksellers/">Booksellers' Information Service</option>
<option value="http://www.oup.co.uk/oxed/children/">Children's Fiction and Poetry</option>
<option value="http://www.oup.co.uk/oxed/children/">Children's Reference</option>
<option value="http://www.oup.co.uk/corporate/">Corporate &amp; Special Sales</option>
<option value="http://www.oup.co.uk/dictionaries/">Dictionaries</option>
<option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
<option value="http://www.oup.co.uk/digital_reference/">Digital Reference</option>
<option value="http://www.oup.com/elt/">English Language Teaching</option>
<option value="http://www.oup.co.uk/best.textbooks/">Higher Education Textbooks</option>
<option value="http://www.oup.co.uk/academic/humanities/">Humanities</option>
<option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
<option value="http://www.oup.co.uk/law/">Law</option>
<option value="http://www.oup.co.uk/academic/medicine/">Medicine</option>
<option value="http://www.oup.co.uk/music/">Music</option>
<option value="http://www.oup.com/online">Online Products</option>
<option value="http://www.oed.com/">Oxford English Dictionary</option>
<option value="http://www.oup.co.uk/reference/">Reference</option>
<option value="http://www.oup.co.uk/rights/">Rights and Permissions</option>
<option value="http://www.oup.co.uk/academic/science/">Science</option>
<option value="http://www.oup.co.uk/oxed/">School Books</option>
<option value="http://www.oup.co.uk/academic/socsci/">Social Sciences</option>
<option value="http://www.oup.co.uk/general/vsi/">Very Short Introductions</option>
<option value="http://www.oup.co.uk/worldsclassics/">World's Classics</option>
</select>
<input src="Hoffman%202007%20DNA%20bar%20coding%20and%20pyrosequencing%20to%20identify%20rare%20HIV%20drug%20resistance%20mutations_files/go.gif" alt="Go" class="inline_button" type="image">
</div>
</form>
</div>
</div>
</div>
<!-- /footer.mc ends -->




</body></html>